Karin Jorga

2.5k total citations
48 papers, 2.0k citations indexed

About

Karin Jorga is a scholar working on Neurology, Psychiatry and Mental health and Oncology. According to data from OpenAlex, Karin Jorga has authored 48 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Neurology, 11 papers in Psychiatry and Mental health and 10 papers in Oncology. Recurrent topics in Karin Jorga's work include Parkinson's Disease Mechanisms and Treatments (11 papers), Epilepsy research and treatment (11 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Karin Jorga is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (11 papers), Epilepsy research and treatment (11 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Karin Jorga collaborates with scholars based in Switzerland, United States and United Kingdom. Karin Jorga's co-authors include Neil Parrott, Hannah M. Jones, G. Zürcher, Monique Schmitt, Jasper Dingemanse, G Sędek, P. van Brummelen, Eric Snoeck, Eric Van Cutsem and P. Heizmann and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer Research.

In The Last Decade

Karin Jorga

48 papers receiving 1.9k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Karin Jorga 415 388 382 325 315 48 2.0k
Michael Cole 501 1.2× 688 1.8× 1.1k 2.8× 215 0.7× 537 1.7× 94 3.2k
Guy Montay 89 0.2× 658 1.7× 442 1.2× 236 0.7× 296 0.9× 60 2.0k
José M. Ladero 108 0.3× 386 1.0× 580 1.5× 742 2.3× 330 1.0× 72 1.9k
Young‐A Heo 152 0.4× 218 0.6× 561 1.5× 66 0.2× 257 0.8× 53 1.8k
Ziad Hussein 57 0.1× 325 0.8× 229 0.6× 201 0.6× 142 0.5× 99 1.9k
Troels K. Bergmann 51 0.1× 719 1.9× 457 1.2× 333 1.0× 107 0.3× 44 2.1k
Michel Lemaire 54 0.1× 952 2.5× 619 1.6× 279 0.9× 147 0.5× 62 2.4k
Mark Avigan 97 0.2× 620 1.6× 966 2.5× 938 2.9× 969 3.1× 71 3.5k
Stacy S. Shord 198 0.5× 1.0k 2.7× 714 1.9× 458 1.4× 129 0.4× 69 2.7k
Liyan Miao 76 0.2× 229 0.6× 547 1.4× 317 1.0× 113 0.4× 129 2.0k

Countries citing papers authored by Karin Jorga

Since Specialization
Citations

This map shows the geographic impact of Karin Jorga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Jorga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Jorga more than expected).

Fields of papers citing papers by Karin Jorga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Jorga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Jorga. The network helps show where Karin Jorga may publish in the future.

Co-authorship network of co-authors of Karin Jorga

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Jorga. A scholar is included among the top collaborators of Karin Jorga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Jorga. Karin Jorga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
García, José Manuel Pérez, Javier Cortés, Elena Miranda, et al.. (2020). 562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex. Annals of Oncology. 31. S484–S485. 1 indexed citations
2.
Graham, Richard, Bert L. Lum, Sravanthi Cheeti, et al.. (2011). Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. Clinical Cancer Research. 17(8). 2512–2520. 97 indexed citations
3.
Graham, Richard, Bert L. Lum, Glenn Morrison, et al.. (2011). A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry. Drug Metabolism and Disposition. 39(8). 1460–1467. 48 indexed citations
4.
5.
Silber, Hanna E., Nicolas Frey, Ronald Gieschke, et al.. (2007). An Integrated Glucose‐Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 Diabetics. The Journal of Clinical Pharmacology. 47(10). 1244–1255. 61 indexed citations
6.
Wade, Janet R., Eric Snoeck, Franck Le Duff, Matthew W. Lamb, & Karin Jorga. (2006). Pharmacokinetics of ribavirin in patients with hepatitis C virus. British Journal of Clinical Pharmacology. 62(6). 710–714. 44 indexed citations
7.
Snoeck, Eric, Janet R. Wade, Franck Le Duff, Matthew W. Lamb, & Karin Jorga. (2006). Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirin. British Journal of Clinical Pharmacology. 62(6). 699–709. 69 indexed citations
8.
Jones, Hannah M., et al.. (2006). A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics. Clinical Pharmacokinetics. 45(5). 511–542. 273 indexed citations
9.
Coleman, Michael D., et al.. (2002). Studies on the toxicity and efficacy of some ester analogues of dapsone in vitro using rat and human tissues. Environmental Toxicology and Pharmacology. 12(1). 7–13. 1 indexed citations
10.
Jorga, Karin. (2000). Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone. Clinical Pharmacology & Therapeutics. 67(6). 610–620. 16 indexed citations
11.
Jorga, Karin, et al.. (2000). Effect of Tolcapone on the Haemodynamic Effects and Tolerability of Desipramine. European Neurology. 44(2). 94–103. 2 indexed citations
12.
Jorga, Karin, et al.. (2000). Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. British Journal of Clinical Pharmacology. 49(1). 39–48. 14 indexed citations
13.
Jorga, Karin & David Nicholl. (1999). COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®). British Journal of Clinical Pharmacology. 48(3). 449–452. 3 indexed citations
14.
Jorga, Karin, et al.. (1999). Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase. British Journal of Clinical Pharmacology. 48(4). 513–520. 66 indexed citations
15.
Jorga, Karin, et al.. (1999). The effect of tolcapone on the pharmacokinetics of benserazide. European Journal of Neurology. 6(2). 211–219. 10 indexed citations
16.
Jorga, Karin, et al.. (1998). The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. Journal of Neurology. 245(4). 223–230. 33 indexed citations
17.
Jorga, Karin, et al.. (1998). Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites*. Clinical Pharmacology & Therapeutics. 63(6). 646–654. 24 indexed citations
18.
Jorga, Karin, et al.. (1997). Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly*. Clinical Pharmacology & Therapeutics. 62(3). 300–310. 38 indexed citations
19.
Jorga, Karin, et al.. (1997). The Effect of COMT Inhibition by Tolcapone on Tolerability and Pharmacokinetics of Different Levodopa/Benserazide Formulations. European Neurology. 38(1). 59–67. 23 indexed citations
20.
Dingemanse, Jasper, Karin Jorga, Monique Schmitt, et al.. (1995). Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans*. Clinical Pharmacology & Therapeutics. 57(5). 508–517. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Cole Breakdown of academic impact, for papers by Guy Montay Breakdown of academic impact, for papers by José M. Ladero Breakdown of academic impact, for papers by Young‐A Heo Breakdown of academic impact, for papers by Ziad Hussein Breakdown of academic impact, for papers by Troels K. Bergmann Breakdown of academic impact, for papers by Michel Lemaire Breakdown of academic impact, for papers by Mark Avigan Breakdown of academic impact, for papers by Stacy S. Shord Breakdown of academic impact, for papers by Liyan Miao
Rankless by CCL
2026